GOG GYN-LIVE

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
★ Support this podcast ★

What is GOG GYN-LIVE?

Welcome to the official podcast of The GOG Foundation, Inc.—a nonprofit organization dedicated to advancing excellence in clinical and scientific research for gynecologic cancers. From ovarian and uterine to cervical, vaginal, and vulvar malignancies, our investigators and institutions are at the forefront of innovation, shaping the future of cancer care.
Each episode features leading experts, groundbreaking trial insights, and real-world stories that illuminate the evolving landscape of gynecologic oncology. Whether you're a clinician, researcher, patient advocate, or survivor, join us as we explore the science, the people, and the progress driving better outcomes and quality of life for patients everywhere.